不孕症藥物市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球不孕症藥物市場規模達40億美元，預計2034年將以6.2%的複合年成長率成長，達到73億美元。這一穩定成長主要源自於全球不孕症的上升，而生活方式、行為和生理因素是導致此現象的因素之一。近年來，現代生活習慣，例如高壓力、不健康飲食、肥胖症盛行率上升以及延遲生育的趨勢，共同導致了所有性別的生育率下降。此外，環境因素和體力活動減少也對生殖健康產生了重大影響。

隨著人們對生育問題的認知不斷提高，越來越多的人開始尋求醫療干預，從而推動了對有效不孕症藥物的需求。隨著生育問題日益普遍，醫療保健提供者越來越重視早期診斷和藥物解決方案，這將繼續提升市場前景。此外，生殖醫學技術的進步和更廣泛的可及治療方案正在擴大市場在已開發地區和發展中地區的覆蓋範圍。

就藥物類別而言，促性腺激素成為主導類別，2024年收入達17億美元。這些藥物在刺激排卵和提高受孕幾率方面發揮關鍵作用，使其成為生育專家和患者的首選藥物。其增強生育能力的能力使其在市場上表現強勁，並被廣泛臨床應用。促性腺激素在控制性卵巢刺激中的有效性及其在各種輔助生殖技術中的應用是其持續需求的關鍵原因。隨著荷爾蒙治療方案的不斷進步，促性腺激素細分市場預計將在整個預測期內實現健康成長。

依給藥途徑分析，不孕症藥物可分為口服、注射及外用。口服藥物在2024年佔據全球市場佔有率的58.1%，佔據主導地位。其主導地位主要歸功於藥丸治療的便利性，顯著提高了患者的依從性。與注射劑相比，口服藥物也更具成本效益且更易於給藥，使其成為長期使用的理想選擇。常見的口服藥物，例如用於一線治療方案的藥物，被醫療保健提供者廣泛用於誘導排卵。非侵入性和居家治療方案的日益普及，進一步推動了口服藥物在患者中的普及，進一步推動了該領域的成長。

按性別分類，2024年，女性群體佔據了全球不孕症藥物市場的絕大部分佔有率，預計到2034年，複合年成長率將達到6.5%。這一成長趨勢的驅動力在於女性不孕症病例的不斷上升，這導致對標靶治療的需求不斷成長。市場收入的很大一部分來自專門針對荷爾蒙失衡、排卵障礙和其他女性生殖健康問題的治療。醫療意識的不斷提高，加上醫療服務和生育診所的便利性不斷提高，正在鼓勵更多女性尋求早期治療，從而維持該領域的成長勢頭。

從分銷管道來看，醫院藥房在2024年引領了全球不孕症藥物市場，預計到2034年將達到42億美元的市場規模。這些藥房提供種類繁多的專科藥物，確保患者在醫院內能夠可靠地取得不孕症藥物。隨著越來越多的患者因不孕症問題而選擇醫院治療，這些機構具備在專業監督下提供必要藥物的條件。不孕症負擔日益加重，以及對有效、及時干預措施的需求，使得醫院藥房成為治療生態系統中至關重要的組成部分。

從區域來看，北美佔據全球不孕症藥物市場的主導地位，2024 年的市佔率為 42.6%。光是美國市場在 2024 年就達到了 15.4 億美元，高於 2023 年的 14.6 億美元。這一強烈的區域影響力可歸因於完善的醫療基礎設施、對生育相關問題的廣泛認知以及先進生殖治療手段的廣泛採用。眾多 FDA 批准的藥物和個人化治療方案的出現，使得美國市場特別活躍。該地區的診所配備了先進的診斷工具和治療方案，包括荷爾蒙療法和促排卵劑，所有這些都有助於為尋求生育治療的患者帶來良好的治療效果。

不孕症藥物市場的競爭仍然激烈，領先的製藥公司正努力透過創新和擴張來鞏固其地位。輝凌製藥、默克、拜耳和輝瑞等主要公司合計佔了全球約60%至65%的市佔率。這些公司持續投資於研發、新產品發布和全球合作夥伴關係，以保持其領先地位。同時，規模較小的區域性企業也透過提供經濟高效的藥物替代品並擴大其產品組合來加劇競爭。隨著企業尋求提升自身能力和地域覆蓋範圍，併購等策略性措施在整個產業中屢見不鮮。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 全球不孕症盛行率不斷上升
    • 隨著女性老化人口的增加，醫療保健意識不斷提高
    • 增加不孕症藥物研發的資金投入
  • 產業陷阱與挑戰
    • 不孕症藥物的副作用和風險
  • 市場機會
    • 輔助生殖技術（ART）的需求不斷成長
    • 擴大新興市場不孕症治療的可近性
• 成長潛力分析
• 監管格局
• 2024年各國生育率
• 管道分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按藥物類別，2021 - 2034 年

• 主要趨勢
• 促性腺激素
• 芳香化酶抑制劑
• 選擇性雌激素受體調節劑（SERM）
• 多巴胺激動劑
• 其他藥物類別

第6章：市場估計與預測：按管理路線，2021 - 2034 年

• 主要趨勢
• 口服
• 腸外
• 外用

第7章：市場估計與預測：依性別，2021 - 2034 年

• 主要趨勢
• 女性
• 男性

第8章：市場估計與預測：按配銷通路，2021 - 2034 年

• 主要趨勢
• 醫院藥房
• 專業藥局和零售藥局
• 網路藥局

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Abbott Laboratories
• Bayer
• Besins Healthcare
• EMD Serono (Merck KGaA)
• Ferring Pharmaceuticals
• Intas Pharmaceuticals
• Livzon
• Mankind Pharma
• Merck & Co.
• Novartis
• Organon & Co.
• Pfizer
• Sanofi
• Sun Pharmaceutical
• Teva Pharmaceutical

The Global Infertility Drugs Market was valued at USD 4 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 7.3 billion by 2034. This steady growth is primarily propelled by a global rise in infertility rates, attributed to a combination of lifestyle, behavioral, and physiological factors. In recent years, modern lifestyle habits such as high stress levels, unhealthy diets, increased prevalence of obesity, and the trend of delaying parenthood have collectively contributed to declining fertility across all genders. Moreover, environmental influences and reduced physical activity are also significantly impacting reproductive health.

As awareness of fertility issues grows, more individuals are seeking medical intervention, thereby driving demand for effective infertility medications. With fertility challenges becoming increasingly common, healthcare providers are emphasizing early diagnosis and pharmaceutical solutions, which continue to enhance the market outlook. Additionally, technological improvements in reproductive medicine and a wider range of accessible treatment options are expanding the market's footprint across both developed and developing regions.

In terms of drug classes, gonadotropins emerged as a dominant category, generating USD 1.7 billion in revenue in 2024. These drugs play a pivotal role in stimulating ovulation and improving the chances of conception, which makes them a preferred choice for fertility specialists and patients alike. Their ability to enhance fertility outcomes contributes to their strong market performance and widespread clinical adoption. The effectiveness of gonadotropins in controlled ovarian stimulation and their use in various assisted reproductive techniques are key reasons behind their sustained demand. With ongoing advancements in hormone therapy protocols, the gonadotropin segment is poised to register healthy growth throughout the forecast period.

When analyzed by route of administration, infertility drugs are segmented into oral, parenteral, and topical forms. The oral segment took the lead in 2024, capturing 58.1% of the global market. Its dominance is largely due to the ease and convenience of pill-based treatments, which significantly boost patient compliance. Oral medications are also more cost-effective and easier to administer compared to injectable forms, making them ideal for long-term use. Common oral agents, such as those used in first-line treatment protocols, are widely prescribed by healthcare providers for ovulation induction. The segment growth is further fueled by the growing preference for non-invasive and home-based treatment regimens, making oral options more popular among patients.

On the basis of gender, the female segment accounted for the majority share of the global infertility drugs market in 2024 and is expected to witness a CAGR of 6.5% through 2034. This growth trend is driven by a rising incidence of female infertility cases, which has led to an increased demand for targeted therapies. A significant portion of the market's revenue comes from treatments designed specifically for hormonal imbalances, ovulation disorders, and other female reproductive health issues. Growing medical awareness, combined with better access to healthcare services and fertility clinics, is encouraging more women to seek early treatment, thereby sustaining this segment's momentum.

Based on distribution channels, hospital pharmacies led the global infertility drugs market in 2024 and are projected to generate USD 4.2 billion by 2034. These pharmacies offer a broad range of specialized medications, ensuring reliable access to fertility drugs within hospital premises. As more patients turn to hospital-based treatments for fertility concerns, these settings are well-equipped to provide the necessary medications with professional oversight. The increasing burden of infertility and the demand for effective, timely interventions have made hospital pharmacies a vital part of the treatment ecosystem.

Regionally, North America dominated the global infertility drugs market with a 42.6% share in 2024. The market in the United States alone recorded a value of USD 1.54 billion in 2024, up from USD 1.46 billion in 2023. This strong regional presence can be attributed to a well-established healthcare infrastructure, widespread awareness of fertility-related issues, and high adoption of advanced reproductive treatments. The availability of numerous FDA-approved drugs and personalized treatment plans makes the U.S. market especially dynamic. Clinics in the region are equipped with advanced diagnostic tools and treatment protocols that include hormone therapies and ovulation inducers, all contributing to favorable outcomes for patients seeking fertility care.

Competition in the infertility drugs market remains intense, with leading pharmaceutical companies striving to strengthen their positions through innovation and expansion. Major players like Ferring Pharmaceuticals, Merck KGaA, Bayer, and Pfizer collectively account for about 60% to 65% of the global market share. These companies continue to invest in R&D, new product launches, and global partnerships to maintain their leadership. In parallel, smaller regional players are increasing competition by offering cost-effective drug alternatives and expanding their product portfolios. Strategic moves such as mergers and acquisitions are common across the industry as firms seek to enhance their capabilities and geographic reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Drug class
  • 2.2.3 Route of administration
  • 2.2.4 Gender
  • 2.2.5 Distribution channel
• 2.3 CXO perspectives: strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of infertility worldwide
    • 3.2.1.2 Rising healthcare awareness along with an increasing aging female population
    • 3.2.1.3 Increasing funding for infertility drugs R&D
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and risks associated with infertility drugs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing demand for assisted reproductive technologies (ART)
    • 3.2.3.2 Expanding access to infertility treatments in emerging markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Fertility rates, by country, 2024
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard
• 4.7 Key developments
  • 4.7.1 Merger and acquisition
  • 4.7.2 Partnership and collaboration
  • 4.7.3 New product launches
  • 4.7.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Gonadotropins
• 5.3 Aromatase inhibitors
• 5.4 Selective estrogen receptor modulators (SERMs)
• 5.5 Dopamine agonists
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral
• 6.4 Topical

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Female
• 7.3 Male

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Specialty and retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Bayer
• 10.3 Besins Healthcare
• 10.4 EMD Serono (Merck KGaA)
• 10.5 Ferring Pharmaceuticals
• 10.6 Intas Pharmaceuticals
• 10.7 Livzon
• 10.8 Mankind Pharma
• 10.9 Merck & Co.
• 10.10 Novartis
• 10.11 Organon & Co.
• 10.12 Pfizer
• 10.13 Sanofi
• 10.14 Sun Pharmaceutical
• 10.15 Teva Pharmaceutical